• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • Published: February 2012
  • 70 pages
  • GlobalData

FEATURED COMPANIES

  • Celgene
  • Gilead Sciences
  • Novartis AG
  • S*BIO
  • Sanofi
  • YM BioSciences Inc.
  • MORE

Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Myelofibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Myelofibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myelofibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Myelofibrosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Myelofibrosis Therapeutics - Introduction
2.1 Overview
2.2 Classification of Myelofibrosis
2.2.1 Primary Myelofibrosis
2.2.2 Secondary Myelofibrosis
2.3 Epidemiology
2.4 Etiology and Pathophysiology
2.4.1 Abnormalities of the Hematopoietic Stem Cells
2.4.2 Gene Mutation in JAK2 Enzyme
2.5 Risk Factors
2.6 Symptoms
2.7 Diagnosis of Myelofibrosis
2.7.1 Physical Examination
2.7.2 Full Blood Count
2.7.3 Bone Marrow Examination
2.7.4 Gene Test
2.8 Referral Pathway
2.9 Treatment
2.9.1 Allogeneic Stem Cell Transplantation
2.9.2 Treatment for Anemia
2.9.3 Treatment for Enlarged Spleen
2.9.4 Interferon Alpha
2.9.5 Cytotoxic Agents
2.9.6 Anagrelide
2.9.7 JAK2 Inhibitors
2.10 GlobalData Pipeline Report Guidance
3 Myelofibrosis Therapeutics - Market Characterization
3.1 Major Markets, Market Size (2006-2011)
3.2 Major Markets, Market Forecast (2011-2019)
3.3 Myelofibrosis Therapeutics Market Size (2006-2011) - The US
3.4 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The US
3.5 Myelofibrosis Therapeutics Market Size (2006-2011) - The UK
3.6 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The UK
3.7 Myelofibrosis Therapeutics Market Size (2006-2011) - France
3.8 Myelofibrosis Therapeutics Market Forecast (2011-2019) - France
3.9 Myelofibrosis Therapeutics Market Size (2006-2011) - Germany
3.10 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Germany
3.11 Myelofibrosis Therapeutics Market Size (2006-2011) - Italy
3.12 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Italy
3.13 Myelofibrosis Therapeutics Market Size (2006-2011) - Spain
3.14 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Spain
3.15 Myelofibrosis Therapeutics Market Size (2006-2011) - Japan
3.16 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Myelofibrosis Therapeutics Market
3.17.1 Drivers of the Myelofibrosis Therapeutics Market
3.17.2 Barrier to the Myelofibrosis Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Myelofibrosis Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of Commonly Used Products in the Myelofibrosis Therapeutics Market
4.2.1 5.2.1 Jakafi (ruxolitinib)
4.3 Key Takeaway
5 Myelofibrosis Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Myelofibrosis Therapeutics - Phase III Pipeline
5.2.2 Myelofibrosis Therapeutics - Phase II Pipeline
5.2.3 Myelofibrosis Therapeutics - Phase I/II Pipeline
5.2.4 Myelofibrosis Therapeutics - Phase I Pipeline
5.3 Myelofibrosis Therapeutics Pipeline by Mechanism of Action
5.4 Myelofibrosis Therapeutics Technology Trends Analytical Framework
5.5 Myelofibrosis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Late-stage under Clinical Development
5.6.1 Actimid (pomalidomide)
5.6.2 SAR302503 (TG 101348)
5.7 Key Takeaway
6 Myelofibrosis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Myelofibrosis Clinical Trials
7 Myelofibrosis Therapeutics - Strategic Assessment
7.1 Myelofibrosis Therapeutics - Implications for Future Market Competition
8 Myelofibrosis Therapeutics - Future Players in the Market
8.1 Introduction
8.1.1 Sanofi
8.1.2 Celgene
8.1.3 Gilead Sciences
8.1.4 YM BioSciences Inc.
8.1.5 Novartis AG
8.1.6 S-BIO
8.1.7 Other Companies in Myelofibrosis Therapeutics Market
9 Myelofibrosis - Licensing and Partnership Deals
10 Myelofibrosis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Myelofibrosis- Prevalence, Major Markets, 2011
Table 2: Causes of Myelofibrosis
Table 3: Classification of Myelofibrosis Patients
Table 4: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011
Table 5: Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Table 6: Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 8: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 9: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 10: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 11: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 12: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 13: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 14: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 15: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 16: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 17: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 18: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 20: Myelofibrosis Therapeutics - Phase III Pipeline
Table 21: Myelofibrosis Therapeutics - Phase II Pipeline
Table 22: Myelofibrosis Therapeutics - Phase I/II Pipeline
Table 23: Myelofibrosis Therapeutics - Phase I Pipeline
Table 24: Myelofibrosis Therapeutics - Promising Drugs under Clinical Development, 2011
Table 25: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011
Table 26: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011
Table 27: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011
Table 28: Myelofibrosis Therapeutics-Overall Sponsors, 2011
Table 29: Myelofibrosis Therapeutics - Prominent Sponsors, 2011
Table 30: Myelofibrosis Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 31: Sanofi - Myelofibrosis Therapeutics Pipeline
Table 32: Cephalon, Inc. - Myelofibrosis Therapeutics Pipeline
Table 33:Gilead Sciences Inc. - Myelofibrosis Therapeutics Pipeline
Table 34: YM BioSciences Inc. - Myelofibrosis Therapeutics Pipeline
Table 35: Novartis AG - Myelofibrosis Therapeutics Pipeline
Table 36: S-BIO- Myelofibrosis Therapeutics Pipeline
Table 37: Myelofibrosis Therapeutics Market- Future Players
Table 38: Myelofibrosis: Licensing and Partnership Deals

1.2 List of Figures
Figure 1:Role of JAK Pathway in Myelofibrosis
Figure 2: Risk Factors for Myelofibrosis
Figure 3: Bone Marrow Biopsy in Myelofibrosis
Figure 4: Referral Pathway
Figure 5: Treatment for Low Risk and High Risk Patients of Myelofibrosis
Figure 6: Treatment for Intermediate Risk Patients of Myelofibrosis
Figure 7: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011
Figure 8:Myelofibrosis Therapeutics Market Share ($m), 2011
Figure 9:Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Figure 10: Myelofibrosis, Market Share ($m), 2019
Figure 11:Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 12: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 13: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 14: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 15: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 16: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 17: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 18: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 19: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 20: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 21: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 22: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 23: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 24: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 25: Myelofibrosis Therapeutics Market, Drivers and Restraints 2011
Figure 26: Opportunity and Unmet Need in the Myelofibrosis Therapeutics Market, 2011
Figure 27: Myelofibrosis Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 28: Myelofibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 29: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline, 2011
Figure 30: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline - Description, 2011
Figure 31: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011
Figure 32: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011
Figure 33: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011
Figure 34: Myelofibrosis Therapeutics - Overall Sponsors, 2011
Figure 35: Myelofibrosis Therapeutics - Prominent Sponsors, 2011
Figure 36: Myelofibrosis Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
Figure 37: Implications for Future Market Competition in the Myelofibrosis Therapeutics Market, 2011
Figure 38: Myelofibrosis Therapeutics Market - Clinical Pipeline by Company, 2011

GlobalData, the industry analysis specialist, has released its new report, “Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global myelofibrosis market. The report identifies the key trends shaping and driving the global myelofibrosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global myelofibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Myelofibrosis Therapeutics Market is Forecast to Show Significant Growth until 2019

GlobalData estimates that the global myelofibrosis therapeutics market was worth $111.1m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 33.7% to $1,133.4m by 2019. The current treatment options for myelofibrosis offer only symptomatic relief and primarily comprise off-label drugs. There are no disease-modifying myelofibrosis drugs, and the drugs in the late stage pipeline also only relieve symptoms, although they have good efficacy and safety profiles. The US Food and Drug Administration (FDA) approved Jakafi in November 2011, which is so far the only approved product for myelofibrosis. As a result, the myelofibrosis market is expected to see significant growth during the forecast period.

The Myelofibrosis Therapeutics Market has Significant Unmet Need

The current treatment options for myelofibrosis are limited. Symptomatic treatment with simple corticosteroids, androgens, immunomodulatory drugs and cytotoxic agents is used but only to relieve the associated symptoms, such as anemia, splenomegaly, fever and sweating during sleep.

The current market lacks disease modifying drugs and consequently the significant unmet need is expected to continue throughout the forecast period. There are no disease-modifying drugs in the late stage of the pipeline, increasing patient reliance on purely symptomatic relief.

Scope for Entrants with Better Efficacy and Safety Profiles

The myelofibrosis market is underserved by the currently marketed drugs as none provide a cure for the disease. As result, there is huge potential for new entrants with drugs that halt or reverse disease progression while simultaneously offering good efficacy and safety profiles. There is also huge potential for novel therapies which offer better symptomatic relief. A convenient route of administration and schedule enhanced long term efficacy and safety profile and cost effectiveness will also prove advantageous.

Sanofi
Celgene
Gilead Sciences
YM BioSciences Inc.
Novartis AG
S*BIO

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos